Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03391804 · ClinicalTrials.gov registry record · Phase 2

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

A Phase 2 study, sponsored by Allena Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target

NCT03391804: Completed Phase 2 study, sponsored by Allena Pharmaceuticals.

NCT03391804 is a Phase 2 study that has completed, run by Allena Pharmaceuticals. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03391804, a Phase 2 study, has completed, sponsored by Allena Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria

Primary Outcome

Efficacy will be assessed based on change from baseline in plasma oxalate

Interventions

  • DRUG ALLN-177

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2018-07-17
Est. Completion 2019-12-13
Phase Phase 2
Allena Pharmaceuticals

11 total trials

What the finished NCT03391804 record still lists

NCT03391804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 1 intervention - of which ALLN-177 is the first listed.

NCT03391804 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03391804 about?

NCT03391804 is a clinical study titled "Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia". Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria

What is the current status of trial NCT03391804?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-07-17. Estimated completion is 2019-12-13.

What interventions are being tested in trial NCT03391804?

The interventions under investigation include: ALLN-177 (DRUG).

Who is sponsoring clinical trial NCT03391804?

This trial is sponsored by Allena Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03391804's enrollment target sits among peer trials

15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03391804, the US trial registry maintained by the National Library of Medicine. NCT03391804 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.